FORE Biotherapeutics to Participate in Upcoming Investor Conferences
FORE Biotherapeutics to Participate in Upcoming Investor Conferences
PHILADELPHIA–(BUSINESS WIRE)–FORE Biotherapeutics today announced that the Company will participate at the following investor conferences:
- Stifel 2024 Healthcare Conference. The Company will attend on Monday, November 18, and will provide a corporate presentation at 2:25 p.m. – 2:55 p.m. ET.
- Jefferies London Healthcare Conference. The Company will attend and participate in one-on-one meetings on Wednesday, November 20, and Thursday, November 21.
Management will host and participate in one-on-one meetings. Please contact Argot Partners to schedule one-on-one meetings with the management team.
About FORE Biotherapeutics
Fore is a registration stage targeted oncology company dedicated to developing innovative treatments that provide better outcomes for patients with the hardest-to-treat cancers. The Company’s lead asset plixorafenib (FORE8394; formerly PLX8394) is a V600 and non-V600 BRAF inhibitor rationally designed with a first-in-class mechanism to address treatment gaps from 1st and 2nd generation BRAF inhibitors. Plixorafenib has demonstrated single-agent efficacy signals across a variety of tumor types with a manageable safety profile in a Phase 1/2a clinical trial of over 100 patients and is currently enrolling patients in a clinical trial with registrational intent in three distinct indications. For more information, please visit www.fore.bio or follow us on X and LinkedIn.
Contacts
Investors and Media:
Argot Partners
212.600.1902 | moc.s1733515040rentr1733515040aptog1733515040ra@oi1733515040BeroF1733515040